Current management of tuberculosis

Bibliography

• DOLIN P, RAVIGLIONE M, KOCHI A: Global tuberculosis incidence and mortality during 1990-2000. Bull. World Health Org. (1994) 72:213–220.
   PubMed Web of Science ®Google Scholar
• MDLULI K, SLAYDEN R, ZHU Y et al.: Inhibition of a Mycobacterium tuberculosis B-ketoacyl ACP synthase by NH. Science (1998) 280:1607–1610.
   PubMed Web of Science ®Google Scholar
• KRUGER-THIEMER E: Isonicotinic acid hypothesis of the antituberculous action of NH. Am. Rev. Tuberc. Pulmon. Dis. (1958) 77:364–367.
   PubMedGoogle Scholar
• MARCINKEVICIENE J, MAGLIOZZO R, BLANCHARD J:Purification and characterisation of the Mycobacte-rium smegmatis catalase-peroxidase. J. Biol. Chem. (1995) 270:22290–22295.
   PubMed Web of Science ®Google Scholar
• BAOHONG J, TRUFFOT-PERNOT C, LACROIX C et al.:Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice. Am. Rev. Respir. Dis. (1993) 148:1541–1546.
   PubMed Web of Science ®Google Scholar
• BROGDEN R, FITTON A: Rifabutin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs (1994) 47:983–1109.
   Google Scholar
• JARVIS B, LAMB H: Rifapentine. Drugs (1998) 56:607–616.
   PubMedGoogle Scholar
• BUNIVA G, PAGANI V, CROZZI A: Bioavailability of rifampicin capsules. Int. J. Clin. Pharmacol. Ther. Toxicol. (1983) 21:404–409.
   PubMedGoogle Scholar
• TAM C, CHAN S, LAM C, DICKINSON J, MITCHISON D:Bioavailability of Chinese rifapentine during a clinical trial in Hong Kong. Int. J. Tuberc. Lung. Dis. (1997) 1:411–416.
   PubMedGoogle Scholar
• DAVIES P: The clinical efficacy of rifabutin in thetreatment of pulmonary tuberculosis. Rev. Contemp. Pharmacother. (1995) 6:121–127.
   Google Scholar
• HORSBURGH C: Advances in the prevention and treatment of Mycobacterium avium disease. New Engl. J. Med. (1996) 335:428–430.
   PubMedGoogle Scholar
• MITCHISON D: Development of rifapentine: the way ahead. Int. J. Tuberc. Lung Dis. (1998) 2:612–615.
   PubMedGoogle Scholar
• MITCHISON D: Pyrazinamide - on the antituberculosis drug frontline. Nature Med. (1996) 2:635–636.
   PubMedGoogle Scholar
• HEIFETS L, LINDHOLM-LEVY P, FLORY M: Thiacetazone:in vitro activity against Mycobacterium avium and Mycobacterium tuberculosis. Tubercle (1990) 71:287–291.
   Google Scholar
• BLANCHARD J: Molecular mechanisms of drug resistance in Mycobacterium tuberculosis. Ann. Rev. Biochem. (1996) 65:215–239.
   Google Scholar
• ••Good review.
   Google Scholar
• GARCIA-RODRIGUEZ J, GOMEZ-GARCIA A: In vitro activities of quinolones against mycobacteria. J. Antimicrob. Chemother. (1993) 32:797–808.
   PubMed Web of Science ®Google Scholar
• GILLESPIE S, KENNEDY N: Fluoroquinolones: a new treatment for tuberculosis? Int. J. Tuberc. Lung Dis. (1998) 2:265–271.
   PubMed Web of Science ®Google Scholar
• MIYAZAKI E, GOOD C, CHEN P et al: Effectiveness of BAY 12-8039 against active tuberculosis in mice. Am. J. Respir. Crit. Care Med. (1998) 157:A467.
   Google Scholar
• DOOLEY D, CARPENTER J, RADEMACHER S: Adjunctive corticosteroid therapy for tuberculosis: a critical reappraisal of the literature. Clin. Infect Dis. (1997) 25:872–887.
   PubMed Web of Science ®Google Scholar
• BILACEROGLU S, PERIM K, BUYUKSIRIN M, CELIKTEN E: Prednisolone: a beneficial and safe adjunct to antitu-berculosis treatment? A randomised controlled trial. Int. J. Tuberc. Lung Dis. (1999) 3:47–54.
   PubMed Web of Science ®Google Scholar
• SNELL N, DAVIES P: New treatments for tuberculosis - whose responsibility? Int. J. Tuberc. Lung Dis. (1997) 1 (Suppl. 1 ):550.
   Google Scholar
• SMITH P, DUNCAN K: Emerging therapeutic targets in tuberculosis: eradication of the causative agent Mycobacterium tuberculosis. Em erg. Ther. Targets (1998) 2(0:87–105.
   Google Scholar
• SNELL N: The treatment of tuberculosis: current statusand future prospects. Exp. Opin. Invest. Drugs (1998) 7(4):545–552.
   PubMedGoogle Scholar
• JOINT TUBERCULOSIS COMMITTEE OF THE BRITISH THORACIC SOCIETY: Chemotherapy and management of tuberculosis in the United Kingdom: recommenda-tions 1998. Thorax (1998) 53:536–548.
   PubMed Web of Science ®Google Scholar
• AMERICAN THORACIC SOCIETY: Treatment of tubercu-losis and tuberculosis infection in adults and children. Am. Rev. Respir. Dis. (1994) 149:1359–1374.
   PubMed Web of Science ®Google Scholar
• TUBERCULOSIS CHEMOTHERAPY CENTRE, MADRAS: A concurrent comparison of home and sanatorium treatment of pulmonary tuberculosis in South India. Bull. World Health Org. (1959) 21:51–144.
   PubMedGoogle Scholar
• CAMPBELL I, ORMEROD L, FRIEND J et al.: Six monthsversus 9 months chemotherapy for tuberculosis of lymph nodes: final results. Respir. Med. (1993) 87:621–623.
   PubMed Web of Science ®Google Scholar
• MEDICAL RESEARCH COUNCIL WORKING PARTY ON TUBERCULOSIS OF THE SPINE: A controlled trial of six-month and nine-month regimens of chemotherapy in patients undergoing radical surgery for tuberculosis of the spine in Hong Kong. Tubercle (1986) 67:243–259.
   PubMedGoogle Scholar
• HUMPHRIES M: The management of tuberculous meningitis. Thorax (1992) 47:577–581.
   PubMed Web of Science ®Google Scholar
• STRANG J, KAKAKA H, GIBSON D et al.: Controlled clinical trial of complete open surgical drainage and of prednisolone in treatment of tuberculous pericardial effusion in Transkei. Lancet (1988) ii:759–763.
   Google Scholar
• STRANG J: Rapid resolution of tuberculous pericardial effusions with high dose prednisone and anti-tuberculous drugs. J. Infection (1994) 28:251–254.
   PubMedGoogle Scholar
• SCHEINMANN P, REFABERT L, DELACOURT C, LE BOURGEOIS M, PAUPE J, DE BLIC J: Paediatric tubercu-losis. Eur. Respir. Mon. (1997) 2(4):144–174.
   Google Scholar
• DAVIES P: Tuberculosis in the elderly. J. Antimicrob. Chemother. (1994) 34: (Suppl. A):93–100.
   Google Scholar
• RAJU B, SCHLUGER N: Tuberculosis and pregnancy. Semin. Respk. Crit. Care Med. (1998) 19:295–306.
   Google Scholar
• PELOQUIN C: Serum concentrations of the antimyco-bacterial drugs. Chest (1998) 113:1154–1155.
   PubMedGoogle Scholar
• MALONE R, FISH D, SPIEGEL D, CHILDS J, PELOQUIN C: The effect of hemodialysis on isoniazid, rifampin, pyrazinamide, and ethambutol. Am. J. Respir. Crit. Care Med. (1999) 159:1580–1584.
   PubMed Web of Science ®Google Scholar
• SCHLUGER N: Issues in the treatment of active tubercu-losis in human immunodeficiency virus-infected patients. Clin. Infect. Dis. (1999) 28:130–135.
   PubMedGoogle Scholar
• NAKATA K, ROM W, HONDA Y et al.: Mycobacterium tuberculosis enhances human immunodeficiency virus-1 replication in the lung. Am. J. Respir. Crit. Care Med. (1997) 155:996–1003.
   PubMed Web of Science ®Google Scholar
• INTERNATIONAL UNION AGAINST TUBERCULOSIS ANDLUNG DISEASE: Treatment regimens in HIV-infected patients. Int. J. Tuberc. Lung Dis. (1998) 2:175–178.
   PubMedGoogle Scholar
• HAVLIR, D, BARNES P: Tuberculosis in patients withhuman immunodeficiency virus infection. New Engl. J. Med. (1999) 340:367–373.
   PubMed Web of Science ®Google Scholar
• VERNON A, BURMAN W, BENATOR D, KHAN A, BOZEMAN L: Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Lancet (1999) 353:1843–1847.
   PubMed Web of Science ®Google Scholar
• NARITA M, ASKHIN D, HOLLENDER E, PITCHENIK A: Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am. J. Respir. Crit. Care Med. (1998) 158:157–161.
   PubMed Web of Science ®Google Scholar
• WHO GENEVA/IUATLD PARIS: Guidelines for surveil-lance of drug resistance in tuberculosis. Int. J. Tuberc. Lung Dis. (1998) 2:72–89.
   PubMedGoogle Scholar
• COHN D, BUSTREO F, RAVIGLIONE M: Drug-resistanttuberculosis: review of the worldwide situation and the WHO/lUATED global surveillance project. Clin. Infect. Dis. (1997) 24 (Suppl. 1):s121–s130.
   Google Scholar
• PABLOS-MENDEZ A, RAVIGLIONE M, LASZLO A: Global surveillance for antituberculosis drug resistance, 1994-1997. New Engl. J. Merl. (1998) 338:1641–1649.
   PubMed Web of Science ®Google Scholar
• TELENTI A: Genetics of drug resistant tuberculosis. Thorax (1998) 53:793–797.
   PubMed Web of Science ®Google Scholar
• BANERJEE S, BHATT K, RANA S, MISRA P, CHAKRABORTI P: Involvement of an efflux system in mediating high levels of fluoroquinolone resistance in Mycobacte-rium smegmatis. Biochem. Biophys. Res. Comm. (1996) 226:362–368.
   PubMed Web of Science ®Google Scholar
• GRANGE J: Vaccination against tuberculosis: past problems and future hopes. Semin. Respir. Crit. Care Merl. (1997) 18:459–470.
   Web of Science ®Google Scholar
• THOMSON N: Efficacy of various durations of isoniazid preventive therapy in tuberculosis: 5 years of follow-up in the lUAT trial. Bull. World Health Org. (1982) 60:555–564.
   PubMedGoogle Scholar
• ORMEROD L: Rifampicin and isoniazid prophylaxis for tuberculosis. Arch. Dis. Child. (1998) 78:169–171.
   PubMed Web of Science ®Google Scholar
• WHALEN C, JOHNSON J, OKWERA A et al: A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. New Engl. J. Merl. (1997) 337:801–808.
   PubMed Web of Science ®Google Scholar
• PATEL A, MCKEON J: Avoidance and management of adverse reactions to antituberculosis drugs. Drug Safety (1995) 12:1–25.
   PubMed Web of Science ®Google Scholar
• GRANGE J, WINSTANLEY P, DAVIES P: Clinically signifi-cant drug interactions with antituberculosis agents. Drug Safety (1994) 11:242–251.
   PubMed Web of Science ®Google Scholar
• KOCHI A: Is DOTS the health breakthrough of the 1990s? World Health Forum (1997) 18:225–247.
   PubMedGoogle Scholar
• BURMON W, DALTON C, COHN D, BUTLER J, RAVES R: A cost-effectiveness analysis of directly observed therapy vs. self-administered therapy for treatment of tuberculosis. Chest (1997) 112:63–70.
   Google Scholar
• FLOYD K, WILKINSON D, GILKS C: Comparison of cost-effectiveness of directly observed treatment (DOT) and conventionally delivered treatment for tuberculosis: experience from rural South Africa. Br. Med. J. (1997) 315:1407–1411.
   PubMedGoogle Scholar
• ZWARENSTEIN M, SCHOEMAN J, VUNDULE C, LOMBARD C, TETLEY M: Randomised controlled trial of self-supervised and directly observed treatment of tuberculosis. Lancet (1998) 352:1340–1343.
   PubMed Web of Science ®Google Scholar
• VOLMINK J, GARNER P: Systematic review of random-ised controlled trials of strategies to promote adherence to tuberculosis treatment. Br. Med. J. (1997) 315:1403–1406.
   PubMed Web of Science ®Google Scholar
• MOULDING T: Medication monitors to treat tubercu-losis. Am. J. Respir. Crit. Care Med. (1999) 159:989–991.
   PubMedGoogle Scholar
• VEEN J, RAVIGLIONE M, RIEDER H et al.: Standardised tuberculosis treatment outcome monitoring in Europe. Eur. Respir. J. (1998) 12:505–510.
   PubMedGoogle Scholar
• ORMEROD L, BENTLEY C: The management of pulmonary tuberculosis notified in England and Wales in 1993. J. R. Coll. Physicians Lond (1997) 31:662–665.
   PubMedGoogle Scholar
• ORMEROD L, BENTLEY C: The management of lymph node tuberculosis notified in England and Wales in 1993. J. R. Coll. Physicians Lond (1997) 31:666–668.
   PubMedGoogle Scholar
• RAO V, IADEMARCO E, FRASER V, KOLLOF M: Delays in the suspicion and treatment of tuberculosis among hospitalised patients. Ann. Intern. Med. (1999) 130:404–411.
   PubMedGoogle Scholar
• REYES H, CONINX R: Pitfalls of tuberculosisprogrammes in prisons. Br. Med. J. (1997) 315:1447–1450.
   PubMed Web of Science ®Google Scholar
• NETTO E, DYE C, RAVIGLIONE M: Progress in globaltuberculosis control 1995-1996, with emphasis on 22 high-incidence countries. Int. J. Tuberc. Lung Dis. (1999) 3:310–320.
   PubMed Web of Science ®Google Scholar